Prostaglandin E1 Testing in Heart Failure-associated Pulmonary Hypertension Enables Transplantation: The PROPHET Study

Journal of Heart and Lung Transplantation

Volumn 25, Issue 9, 2006, Pages 1070-1076

  von Scheidt, Wolfgang ^a   Costard Jaeckle, Angelika ^b   Stempfle, Hans Ulrich ^a   Deng, Mario C ^c   Schwaab, Bernhard ^d   Haaff, Bernd ^e   Naegele, Herbert ^f   Mohacsi, Paul ^g   Trautnitz, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

^e Westpfalz Klinikum GmbH   (Germany)

^f UNIVERSITY OF HAMBURG   (Germany)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1; DIAGNOSTIC AGENT; VASODILATOR AGENT;

ADULT; AORTA PRESSURE; ARTICLE; CORONARY CARE UNIT; FEMALE; GENDER; GERMANY; HEALTH CENTER; HEART EJECTION FRACTION; HEART FAILURE; HEART OUTPUT; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SWITZERLAND; SYMPTOM; VASCULAR RESISTANCE; CLINICAL TRIAL; DRUG EFFECT; FORWARD HEART FAILURE; GRAFT REJECTION; HEART CATHETERIZATION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEMODYNAMICS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; SEX DIFFERENCE;

ADULT; ALPROSTADIL; CARDIAC OUTPUT, LOW; FEMALE; GRAFT REJECTION; HEART CATHETERIZATION; HEART TRANSPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROGNOSIS; SEX FACTORS; STROKE VOLUME; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33748296116     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.04.011     Document Type: Article

References (35)

1. Moraes D.L., Colucci W.S., and Givertz M.M. Secondary pulmonary hypertension in chronic heart failure. Circulation 102 (2000) 1718-1723
2. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327 (1992) 70-75
3. Cooper C.J., Landzberg M.J., Anderson T.J., et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 93 (1996) 266-271
4. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
5. Nootens M., Kaufmann E., Rector T., et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamc variables and endothelin levels. JAMA 26 (1995) 1581-1585
6. Stamler J.S., Loh E., Roddy M.A., et al. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 89 (1994) 2035-2040
7. Chen J.M., Levin H.R., Michler R.M., et al. Cardiac and pulmonary replacement. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 114 (1997) 627-634
8. Costard-Jaeckle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. JAMA 19 (1992) 48-54
9. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan E.J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 9 (1990) 526-537
10. Bourge R.C., Naftel D.C., Costanzo-Nordin M.R., et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study. J Heart Lung Transplant 12 (1993) 549-562
11. Arbeitsgruppe Thorakale Organtransplantation der Deutschen Gesellschaft für Kardiologie- Herz- und Kreislaufforschung. Indikationen, Kontraindikationen und differentialtherapeutische Alternativen der Herztransplantation. Z Kardiol 85 (1996) 519-527
12. Stobierska-Dzierzek B., Awad H., and Michler R.E. The evolving management of acute right-sided heart failure in cardiac transplant recipients. JAMA 38 (2001) 923-931
13. Murali S., Kormos R.L., Uretsky B.F., et al. Preoperative pulmonary hemodynamics and early mortality after ortotopic cardiac transplantation: the Pittsburgh experience. Am Heart J 126 (1993) 896-904
14. Chang P.P., Longenecker C., Wang N.-Y., et al. Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality. J Heart Lung Transplant 24 (2005) 998-1007
15. Deeb G.M., Bolling S.F., Guynn T.P., et al. Amrinone versus conventional therapy in pulmonary hypertensive patients awaiting cardiac transplantation. Ann Thorac Surg 48 (1989) 665-669
16. Kieler-Jensen N., Milocco I., and Ricksten S.E. Pulmonary vasodilatation after heart transplantation. A comparison among prostacyclin, sodium nitroprusside, and nitroglycerin on right ventricular function and pulmonary selectivity. J Heart Lung Transplantat 12 (1993) 179-184
17. Kieler-Jensen N., Ricksten S.E., Stenqvist O., et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13 (1994) 366-375
18. 1, and sodium nitroprusside. J Heart Lung Transplant 14 (1995) 436-443
19. Metha S., Steward J.D., Langleben D., et al. Short-term pulmonary vasodilatation with l-arginine in pulmonary hypertension. Circulation 92 (1995) 1539-1545
20. 1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 11 (1992) 716-723
21. Ooi H., Colucci W.S., and Givertz M.M. Endothelin mediates increased pulmonary vascular tone in patients with heart failure. Circulation 106 (2002) 1618-1621
22. Givertz M.M., Colucci W.S., LeJemtel T.H., et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation 101 (2000) 2922-2927
23. 2 (prostacyclin). Z Kardiol 88 (1999) 133-140
24. 1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant 24 (2005) 690-695
25. Komajda M., Follath F., Swedberg K., et al. The EuroHeart Failure Survey Programme: a survey on quality of care among patients with heart failure in Europe. Eur Heart J 24 (2003) 464-474
26. Galie N., Ussia G., Passarelli P., et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. Am J Cardiol 75 (1995) 55A-62A
27. Loh E., Stamler J.S., Hare J.M., et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 90 (1994) 2780-2785
28. Deng M.C., Edwards L.B., Hertz M.I., et al. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: first annual report 2003. J Heart Lung Transplant 22 (2003) 653-662
29. Kiowski W., Suetsch G., Hunziker P., et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet 346 (1995) 732-736
30. Suetsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 (1998) 2262-2268
31. Cowburn P.J., Cleland J.G., McArthur J.D., et al. Short-term hemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet 352 (1998) 202-203
32. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
33. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (Overture and Enable): approaching the asymptote of efficacy?. J Card Fail 8 (2002) 124-127
34. Stanek B., Sturm B., Frey B., et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 18 (1999) 358-366
35. Klotz S., Deng M.C., Hanafy D., et al. Reversible pulmonary hypertension in heart transplant candidates-pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 5 (2003) 645-653